Device Trial Radar · NCT04795635
Axon Therapy for Post-Traumatic Peripheral Neuropathic Pain Compared to Conventional Medical Management
Last checked: Nov 20, 2026Latest source record: Jul 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
61
Actual
Start
Apr 14, 2021
Primary completion
May 22, 2024
Study completion Aug 22, 2024
Sponsor
- Lead sponsor
- NeuraLace Medical, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 12, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Compare Axon Therapy using transcutaneous magnetic stimulation (tMS) against conventional medical management in treating post-traumatic peripheral neuropathic pain (PTPNP).
Conditions
- Neuropathic Pain
- Peripheral Neuropathy
Interventions
CMM + Axon TherapyDevice
transcutaneous magnetic stimulation (tMS)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of the Proportion of RespondersTime frame: 90 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
National Spine and Pain Centers
Shrewsbury, New Jersey
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.